InvestorsObserver
×
News Home

Concert Pharmaceuticals Inc (CNCE) Down 4.09% in Premarket Trading

Monday, November 08, 2021 07:27 AM | InvestorsObserver Analysts

Mentioned in this article

Concert Pharmaceuticals Inc (CNCE) Down 4.09% in Premarket Trading

Concert Pharmaceuticals Inc (CNCE) has fallen Monday morning, with the stock declining -4.09% in pre-market trading to 3.52. CNCE's short-term technical score of 3 indicates that the stock has traded less bullishly over the last month than 97% of stocks on the market. In the Biotechnology industry, which ranks 142 out of 146 industries, Concert Pharmaceuticals Inc ranks higher than 8% of stocks. Concert Pharmaceuticals Inc has risen 22.74% over the past month, closing at $2.91 on October 11. During this period of time, the stock fell as low as $2.69 and as high as $4.49. CNCE has an average analyst recommendation of Strong Buy. The company has an average price target of $17.00.

Overall Score - 40
CNCE has an Overall Score of 40. Find out what this means to you and get the rest of the rankings on CNCE!
Concert Pharmaceuticals Inc has a Long-Term Technical rank of 34. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 66% of the market scoring higher. In the Biotechnology industry which is number 133 by this metric, CNCE ranks better than 61% of stocks.

Important Dates for Investors in CNCE:

-We do not have a set earnings date for Concert Pharmaceuticals Inc at this time. -We do not have a set dividend date for Concert Pharmaceuticals Inc at this time. Click Here To Get The Full Report on Concert Pharmaceuticals Inc (CNCE)

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App